CAMBRIDGE, MA / ACCESSWIRE / April 25, 2018 / Genprex, Inc.(NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has established offices in Cambridge, Mass. to help accelerate the clinical development of its lead drug candidate, Oncoprex™, for the treatment […]
AUSTIN, Texas, April 18, 2018 /PRNewswire/ — Genprex, Inc., a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today that it has entered an agreement with The University of Texas at Austin Dell Medical School to establish executive offices at the school’s Health Discovery Building, joining the WorkSpaces @ Texas Health CoLab that brings […]
AUSTIN, Texas, April 16, 2018 /PRNewswire/ — Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, today announced a clinical and corporate update. Rodney Varner, Chairman and CEO, remarked, “2017 was a pivotal year for Genprex, laying the groundwork for 2018 and beyond. We are dedicated to developing our novel therapeutic […]
AUSTIN, Texas and CAMBRIDGE, Mass., April 11, 2018 /PRNewswire/ — Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Julien L. Pham, MD, MPH as the Company’s President. In this expanded senior management position, Dr. Pham, who joined Genprex in 2016 as Chief Operating […]
AUSTIN, Texas, April 6, 2018 /PRNewswire/ — Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today that Rodney Varner, Chairman and CEO, will present at The MicroCap Conference to be held in New York City on April 9 and 10, 2018. The Company is scheduled to present on Monday, April 9, 2018 at 4:30 PM EDT. Mr. Varner will […]
AUSTIN, Texas, April 4, 2018 /PRNewswire/ — Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today the closing of its initial public offering on April 3, 2018 of an aggregate of 1,280,000 shares of common stock at a public offering price of $5.00 per share, before underwriting discounts. The Company has also granted […]
